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Abstract 
Purpose: Sunitinib treatment with a 2-week-on/1-week-off schedule (Schedule 2/1) is a 
common alternative regimen with high relative dose intensity (RDI) and superior 
tolerability for patients with metastatic renal cell carcinoma (mRCC). The prognostic 
impact of RDI is reported only in 4-week-on/2-week-off or mixed regimens. Herein, we 
evaluated the prognostic impact of RDI during early-phase sunitinib treatment using 
Schedule 2/1.  
Methods: Seventy-four patients who received first-line sunitinib treatment using Schedule 
2/1 were evaluated. Endpoints were progression-free survival (PFS) and overall survival 
(OS). We assessed RDI within the initial 2 cycles (2c-RDI), and its prognostic impact. 
Predictive factors for 2c-RDI deterioration were also evaluated. 
Results: The cut-off value of 2c-RDI was set at 65%. Based on this cut-off, 31 patients 
(42.0%) were classified into the low 2c-RDI group (<65%). PFS and OS were 
significantly shorter in the low-2c-RDI patients, compared with the high 2c-RDI patients 
(median PFS: 6.15 vs. 18.4 months, p=0.0005; OS: 11.0 vs. 39.3 months, p=0.0002). 
Furthermore, multivariate analyses showed that the development of dose-limiting 
toxicities (DLTs) within the initial two cycles, as well as low initial dose, were 
independent factors for low 2c-RDI (DLTs: OR, 18.6, 95% CI: 3.27–105.30, p=0.0010; 
initial dose: OR, 9.26, 95% CI: 1.42–60.40, p=0.020). The most common adverse event 
was thrombocytopenia (any grade: 24.3%; grade ≥3: 8.1%). 
Conclusions: More than 65% of 2c-RDI should be maintained for optimal therapeutic 
effect of sunitinib treatment using Schedule 2/1. To achieve the appropriate 2c-RDI, 
careful follow-up for patient tolerability is needed to avoid early DLT development.  
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Introduction 
Sunitinib is an orally administered, multi-targeted tyrosine kinase inhibitor that 
exhibits antitumor and antiangiogenic activity [1, 2] and is a preferential option for first-
line, molecular-targeted therapy of patients with metastatic renal cell carcinoma (mRCC) 
[3, 4]. The standard dosing schedule of sunitinib is 4-week-on/2-week-off (Schedule 4/2) 
[5]. However, the frequent development of dose limiting toxicities (DLTs) induced by 
Schedule 4/2 is a serious issue for many patients. To overcome these DLTs, several studies 
have indicated that an alternative 2-week-on/1-week-off schedule (Schedule 2/1) can 
decrease the incidence of adverse events (AEs) and maintain a high relative dose intensity 
(RDI), while providing an equivalent therapeutic effect as Schedule 4/2 [6-11]. Therefore, 
the Schedule 2/1 regimen is broadly applied in real-world clinical practice. 
     The prognostic impact of RDI during early-phase sunitinib treatment has been 
reported [12–14]. However, in these previous studies RDI was calculated in patients who 
received Schedule 4/2, or mixed Schedule 4/2 and 2/1, regimens. Moreover, cytokine 
therapy prior to sunitinib treatment has been performed in previous studies [12,14], 
although the current treatment strategy for mRCC does not preferentially recommend 
cytokine therapy [4,15]. Furthermore, the number of studies which have investigated 
predictive factors for RDI remains limited since it is difficult to predict RDI before or 
during treatment; predictive factors for RDI are necessary for physicians to modulate 
dosage regimens in patients with mRCC. 
Collectively, the aim of this study was to evaluate the prognostic impact and 
predictive factors of RDI during early-phase sunitinib treatment using Schedule 2/1 in 
patients with mRCC who have not received prior cytokine therapy.   
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Material and Methods 
 
Patient selection 
Between January 2007 and March 2017, a total of 118 patients received first-line 
sunitinib treatment for mRCC at our department. We excluded patients who received 
sunitinib treatment with Schedule 4/2 (n = 35), received kidney transplantation (n = 1), 
or received prior cytokine therapy (n = 2). In addition, patients who received sunitinib 
treatment for a short duration (n = 1), or whose detailed data were missing (n=5), were 
excluded from this study. Finally, 74 patients were evaluated in this study (Fig. 1). 
 
Ethical approval 
All the procedures performed in this study were in accordance with the ethical 
standards of the institutional and/or national research committee and with the 1964 
Helsinki Declaration and its later amendments or comparable ethical standards. 
 
Protocol of sunitinib treatment  
In our department, the main agent administered for first-line molecular-targeted 
therapy of mRCC is sunitinib. Recently, we have administered sunitinib with Schedule 
2/1, based on our previous study [6].  
Our protocol for sunitinib treatment has been previously reported [16, 17]. Briefly, 
the standard initial dose of sunitinib is 50 mg/day. However, we considered dose reduction 
if patients had the following criteria: (1) age >65 years, (2) serum creatinine >2 mg/dL, 
and (3) body weight <50 kg. If one of these factors was present, the starting dose was 
reduced to 37.5 mg/day. If two of these factors were present, we then reduced the dose to 
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25 mg/day. The dose of sunitinib was increased by 12.5 mg/day and until we found the 
highest dose a given patient could tolerate; however, the dose never exceeded 50 mg/day.  
 
Follow-up schedule of sunitinib treatment 
Before starting sunitinib, all patients underwent computed tomography imaging to 
evaluate metastasis. During the first course of sunitinib, we followed-up patients on a 
weekly basis at our outpatient clinic, and then every 3 or 6 weeks thereafter. At every 
visit, we assessed patient adverse events and laboratory data. In addition, a CT scan was 
conducted every 12 weeks to evaluate therapeutic effect. Tumor response was assessed 
according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 [18]. 
AEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE) 
of the National Cancer Institute, version 4.0 [19]. Dose reduction and interruption was 
conducted according to guidelines for sunitinib therapy. In these regimens, the drugs were 
administered until disease progression was observed or intolerable adverse events 
developed. 
 
Relative Dose Intensity 
The RDI was determined as the ratio of the cumulative dose that was received 
during the cycle to 1,400 mg. In this study, we calculated the RDI during the initial 2 
cycles (2c-RDI) of sunitinib therapy as an evaluation of early-phase RDI. 
 
Statistical analysis 
Continuous variables were analyzed using the Mann-Whitey U test, and categorical 
variables were analyzed using the χ2 test or Fisher’s exact test. We assessed progression-
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free survival (PFS) and overall survival (OS) after initiating sunitinib treatment as study 
endpoints. PFS was defined as the time from sunitinib treatment initiation to the date of 
disease progression. OS was defined as the time from sunitinib treatment initiation to 
death from any cause. We determined a cut-off value for 2c-RDI and divided patients into 
2 groups according to the cut-off value (i.e., high 2c-RDI and low 2c-RDI group). PFS 
and OS was calculated using the Kaplan-Meier method and compared using the log-rank 
test. Univariate and multivariate logistic regression analyses were used to identify 
predictive factors of 2c-RDI deterioration. Risk was expressed as odds ratios (ORs) and 
95% confidence intervals (CIs). Statistical analyses were performed with JMP software 
(version 13.0; SAS Institute Inc., Cary, NC, USA). All statistical tests were two-sided, 
and p < 0.05 was considered statistically significant. 
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Results 
Patient characteristics 
The patients’ clinicopathological characteristics are shown in Table 1. The median 
age was 64.0 years-old, and 55 patients (74.3%) were male. Sixty-six patients (89.2%) 
underwent prior nephrectomy. Based on the Memorial Sloan-Kettering Cancer Center 
(MSKCC) risk classification, 17 (23.0%), 45 (60.8%), and 12 (16.2%) patients were 
classified as favorable, intermediate, and poor risk, respectively. The initial dose of 
sunitinib was 50.0 mg, 37.5 mg, and 25.0 mg/day in 20 (27.0%), 38 (51.4%), and 16 
(21.6%) patients, respectively. The median 1c-RDI and 2c-RDI were 75.0% and 71.9%, 
respectively. The median follow-up period was 25.9 months. 
 
Cut-off value of 2c-RDI 
We examined cut-off values of 2c-RDI at 5.0% intervals from an initial cut-off value of 
80% and conducted a univariate analysis of treatment results at PFS and OS. 
Consequently, a cut-off value of 65% was found to be a strongly associated value after 
evaluating the p-values of various 2c-RDI cut-off values, by selecting the cut-off value 
with the lowest p-value (Table 2). Based on this cut-off value, 31 (41.9%) and 43 patients 
(58.1%) were classified into low (<65%) and high (≥65%) 2c-RDI groups, respectively. 
According to the 65% cut-off value, PFS was significantly shorter in patients with low-
2c-RDI compared to those with high 2c-RDI (median PFS: 6.15 months [95% CI: 3.68–
8.84] vs. 18.4 months [95% CI: 11.1–47.0], p = 0.0005). Moreover, OS was also shorter 
in patients with low 2c-RDI (median OS: 11.0 months [95% CI: 8.42–21.80] vs. 39.3 
months [95% CI: 26.6–not reached], p = 0.0002) (Fig. 2). Furthermore, as for differences 
in patient characteristics based on the 65% 2c-RDI cut-off value, older age, female gender, 
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lower initial dose, and higher frequency of DLTs were associated with the low 2c-RDI 
group (all variables, p <0.05) (Supplementary Table 1). 
 
Predictive factors for 2c-RDI 
 Univariate and multivariate logistic regression analyses showed that DLT 
development within the initial 2 cycles of sunitinib and low initial dose were independent 
factors for low 2c-RDI (initial dose: OR, 9.26, 95% CI: 1.42–60.40, p = 0.020; DLTs: OR, 
18.6, 95% CI: 3.27–105.30, p = 0.0010) after adjustment for other factors including sex, 
age, body weight, MSKCC risk factor, and serum creatinine levels (Table 3).  
  
Adverse events induced by dose limiting toxicities during the initial two cycles 
Table 5 shows the individual DLTs requiring dose reduction or treatment 
interruption during the initial 2 cycles of sunitinib. Twenty patients (27.0%) and 23 
patients (31.1%) experienced dose reduction and treatment interruption due to DLTs, 
respectively. For any grade, thrombocytopenia was the most common AE observed in 18 
patients (24.3%), followed by hand-foot syndrome (n = 10, 13.5%) and leukocytopenia 
(n = 9, 12.2%). For grade ≥3, thrombocytopenia and leukocytopenia were the most 
common AEs (both, n = 6, 8.1%), followed by anorexia and hepatic dysfunction (n = 2, 
2.7%).  
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Discussion 
In this study, we examined the RDI and DLT profiles using a Schedule 2/1 in 
patients receiving sunitinib treatment for mRCC. Patients with at least 65% of 2c-RDI 
had a significantly longer PFS and OS compared to those with less than 65% of 2c-RDI. 
In addition, early DLT development and low initial dose were independent factors for low 
2c-RDI. Furthermore, hematotoxic AEs, such as thrombocytopenia and leukopenia, 
comprised of most DLTs in this study. To the best of our knowledge, this is the first study 
to indicate the prognostic impact and predictive factors for RDI during early-phase 
sunitinib treatment using Schedule 2/1 without receiving prior cytokine therapy. 
The prognostic impact of RDI during early-phase sunitinib treatment using 
Schedule 4/2 was previously reported [12-14]. Kawashima et al. showed that 60% of the 
one-month RDI was an important indicator for survival, and Porta et al. showed that 
patients below 70% of the RDI had shorter OS. Considering these findings, the threshold 
of 65% adopted in our analysis was consistent with previous findings. 
We found that two factors, early DLT development and initial dose, were predictive 
of 2c-RDI deterioration. As expected, the initial dose was directly associated with 2c-
RDI. Therefore, when the initial dose was ≤25.0 mg/day due to patient factors (as shown 
in Materials and Methods), administration of another targeted agent other than sunitinib, 
can be an optimal treatment choice. More importantly, DLT development significantly 
affected 2c-RDI after adjustment of the initial dose. Therefore, to maintain the therapeutic 
efficacy of sunitinib, particular attention should be paid for patient tolerability to avoid 
early DLT development. 
Several studies reported favorable tolerability and feasibility of sunitinib treatment 
with Schedule 2/1, compared to that with the standard Schedule 4/2 [6-11]. We previously 
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reported that AE incidence rates did not differ between Schedule 2/1 and Schedule 4/2, 
and treatment interruption was less frequently observed in Schedule 2/1 [6]. Miyake et al. 
showed that the incidence rates of ≥grade 3 AEs were significantly low, and a favorable 
health-related quality of life was observed for Schedule 2/1 [9]. In the present study, 
31.1% of patients experienced treatment interruption. Since 60% of patients experienced 
treatment interruption with Schedule 4/2 according to previous data from a large Japanese 
population-based study [20], this study supports the idea that the alternative Schedule 2/1 
regimen has superior tolerability. 
We also found that hematotoxicity majorly composed of DLTs. These types of AEs 
are difficult to monitor using patient symptoms. As previously discussed, early DLT 
development and initial dose can deteriorate 2c-RDI. Therefore, for the patients with 
severe hematotoxic AEs, switching the therapeutic agent to another drug (e.g., pazopanib) 
can be an effective option. Initiating treatment with pazopanib may be advantageous for 
patients who are less susceptible to RDI, such as elderly female patients. Indeed, 
pazopanib was demonstrated to be more tolerable and had less hematotoxicity risk, when 
compared to sunitinib [21, 22]. 
This study had several limitations. First, this was a retrospective study performed 
at a single center with a small cohort size. Therefore, unavoidable biases for patient or 
treatment selection may exist. Moreover, due to the retrospective nature, all AEs may not 
have been recognized and any unrecorded AEs could affect our analyses. Second, our 
findings were obtained from results collected in the clinical setting. Therefore, all 
treatment modifications, such as dose reduction and treatment interruption, were not 
conducted based on treatment guidelines. Third, several studies reported the differences 
in AE profiles between Asian and Western populations [23–26]. Taken together, our 
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findings should be confirmed by a further prospective study performed on a large 
population, including Western patients. 
In conclusion, this study showed that more than 65% of 2c-RDI was necessary to 
maintain therapeutic efficacy for sunitinib treatment using a 2-week-on/1-week-off 
schedule. Furthermore, DLT development and initial dose were predictive factors for 2c-
RDI deterioration. Therefore, careful monitoring of patient tolerability for this treatment 
regimen is needed.  
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Figure legends 
 
Fig. 1: Study design. 
 
Fig. 2: Progression-free and overall survivals according to 65% of relative dose 
intensity during the initial two cycles. 
Patients with <65% of relative dose intensity during the initial two cycles (n = 31) had 
significantly shorter progression-free survival (median: 6.15 months [95% CI: 3.68–8.84] 
vs. 18.4 months [95% CI: 11.1–47.0], p = 0.0005) and overall survival (median: 6.84 
months [95% CI: 4.57–14.3] vs. 28.4 months [95% CI: 14.7–not reached], p = 0.0002), 
as compared to those with ≥65% of relative dose intensity (n = 43). 
RDI, relative dose intensity; PFS, progression-free survival; OS, overall survival; CI, 
confidence interval 
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Table 1. Patient characteristics 
 n = 74 
* Age (year-old) 64.0 (59.8–69.3) 
Sex Male 55 (74.3%) 
Female 19 (25.7%) 
*BMI (kg/m2) 23.1(20.9–24.9) 
Prior nephrectomy With 
Radical 
Partial 
66 (89.2%) 
63 (85.1%) 
3 (4.1%) 
Without 8 (10.8%) 
Metastatic sites Lung 
Liver 
Bone 
Lymph nodes 
44 (59.5%) 
10 (13.5%) 
18 (24.3%) 
29 (39.2%) 
Pathology Clear cell carcinoma 55 (74.3%) 
Non- clear cell carcinoma 
Papillary renal cell carcinoma II 
Clear cell carcinoma with spindle cell 
Others/Unknown 
19 (25.7%) 
4 (5.4%) 
5 (6.8%) 
10 (13.5%) 
MSKCC risk Favorable 
Intermediate 
Poor 
17 (23.0%) 
45 (60.8%) 
12 (16.2%) 
*Serum creatinine level (mg/dL) 1.27 (1.00–1.84) 
*Serum CRP level (mg/dL) 0.50 (0.23–4.20) 
Initial dose (mg) 50 mg 
37.5 mg 
25 mg 
20 (27.0%) 
38 (51.4%) 
16 (21.6%) 
*Follow-up periods (months) 25.9 (10.7–45.2) 
*1 cycle-RDI (%) 75.0 (61.8–84.8) 
*2 cycle-RDI (%) 71.9 (55.5–77.4)  
DLTs With 43 (58.1%) 
Without 31 (41.9%) 
* Median (interquartile range) 
MSKCC, Memorial Sloan-Kettering Cancer Center; CRP, C-reactive protein; BMI, Body Mass Index; RDI, relative dose intensity; DLTs, dose limiting 
toxicities 
Table 2. Comparisons of survivals after sunitinib treatment according to cut-off values of relative dose intensity during initial two 
cycles 
Cut-off value, %  n 
PFS 
HR 
95% CI p-value 
OS 
HR 
95% CI p-value 
< 80 vs. ≥ 80 57 vs. 17 1.26 0.65–2.67 0.513 1.51 0.70–3.73 0.308 
75 38 vs. 36 2.36 1.32–4.32 0.0038 2.50 1.30–5.06 0.0057 
70 36 vs. 38 2.22 1.24–4.01 0.0071 2.70 1.41–5.36 0.0027 
65 31 vs. 43 2.69 1.49–4.83 0.0011 3.22 1.69–6.28 0.0004 
60 26 vs. 48 2.36 1.28–4.24 0.0062 2.44 1.27–4.63 0.0078 
PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; OS, overall survival 
Table 3. Univariate and multivariate analyses for the factors influencing 2c-RDI 
 
Univariate Multivariate 
OR (95% CI) p-value OR (95% CI) p-value 
Sex  
Female (vs. male) 
4.45 (1.45–13.6) 0.0138 4.09 (0.85–19.6) 0.078 
Age 
≥ 65 years-old (vs. ＜ 65 years-old) 
3.07 (1.17–8.02) 0.0333 2.89 (0.78–10.7) 0.111 
Body weight 
< 50 kg (vs. ≥ 50 kg) 
3.89 (0.92–16.5) 0.0834 5.15 (0.57–46.5) 0.144 
MSKCC risk 
 Poor (vs. favorable/intermediate) 
 0.95(0.29–3.09) 1.00 1.09 (0.21–5.51) 0.920 
Serum creatinine level 
> 2.0 mg/dL (vs. ≤ 2.0 mg/dL) 
0.65 (0.18–2.38) 0.750 1.62 (0.25–10.3) 0.610 
Initial dose 
< 37.5 mg (vs. ≥ 37.5 mg) 
6.16 (1.75–21.7) 0.0037 9.26 (1.42–60.4) 0.020 
DLTs within 2cycle 
 with (vs. without) 
7.95 (2.55–24.8) 0.0001 18.6 (3.27–105.3) 0.0010 
RDI, relative dose intensity; OR, odds ratio; MSKCC, Memorial Sloan-Kettering Cancer Center; DLTs, dose limiting toxicities 
Table 4. Dose limiting toxicities during initial two cycles of sunitinib treatment 
 Any grade Grade ≥ 3 
Dose reduction 20 (27.0%) 5 (6.6%) 
Treatment interruption  23 (31.1%) 13 (17.6%) 
Adverse events requiring in dose reduction or interruption 
Thrombocytopenia 18 (24.3%) 6 (8.1%) 
Hand-foot syndrome 10 (13.5%) 0 
Leukopenia 9 (12.2%) 6 (8.1%) 
Anorexia 8 (10.8%) 2 (2.7%) 
Diarrhea 7 (9.5%) 0 
Hepatic dysfunction 6 (8.1%) 2 (2.7%) 
Fatigue 6 (8.1%) 0 
Renal dysfunction 4 (5.4%) 0 
Fever 3 (4.1%) 0 
Stomatitis 2 (2.7%) 0 
Hyperkalemia 1 (1.4%) 1 (1.4%) 
Nausea 1 (1.4%) 0 
Hematuria 1 (1.4%) 0 
Interstitial pneumonia 1 (1.4%) 0 
Amylase increased 1 (1.4%) 0 
Supplementary Table 1. Patient characteristics 
 Low 2c-RDI 
(n = 31) 
High 2c-RDI 
(n = 43) 
P value 
* Age (year-old) 68.0 (63–72) 63 (56–67) 0.001 
Sex Male 18 (58.1%) 37 (86.0%) 
0.0138 
Female 13 (41.9%) 6 (14.0%) 
*BMI (kg/m2) 23.1 (20.5–24.3) 23.5 (21.4–25.3) 0.906 
Prior nephrectomy With 
Radical 
Partial 
26 (83.9%) 
26 (83.9%) 
0 
40 (93.0%) 
37 (86.0%) 
3 (7.0%) 
0.674 
Without 5 (16.1%) 3 (7.0%) 
Metastatic sites Lung 
Liver 
Bone 
Lymph nodes 
19 (61.3%) 
6 (19.4%) 
9 (29.0%) 
15 (48.4%) 
25 (58.1%) 
4 (9.3%) 
9 (20.9%) 
14 (32.6%) 
0.815 
0.304 
0.584 
0.228 
Pathology Clear cell carcinoma 20 (64.5%) 35 (81.4%) 
0.115 
Non- clear cell carcinoma 
Papillary renal cell carcinoma II 
Clear cell carcinoma with spindle cell 
Others/Unknown 
11 (35.5%) 
3 (9.7%) 
4 (12.9%) 
4 (12.9%) 
8 (18.6%) 
1 (2.3%) 
1 (2.3%) 
6 (14.0%) 
MSKCC risk Favorable 
Intermediate 
Poor 
4 (12.9%) 
21 (67.7%) 
6 (19.4%) 
16 (37.2%) 
19 (44.2%) 
8 (18.6%) 
0.057 
*Serum creatinine level (mg/dL) 1.12 (0.82–1.61) 1.38 (1.02–1.97) 0.27 
*Serum CRP level (mg/dL) 0.66 (0.31–4.62) 0.39 (0.21–3.37) 0.64 
Initial dose (mg) 50 mg 
37.5 mg 
25 mg 
3 (9.7%) 
16 (51.6%) 
12 (38.7%) 
17 (39.5%) 
22 (51.2%) 
4 (9.3%) 
0.0001 
*Follow-up periods (months) 11.8 (6.74–34.4) 31.2 (21.1–50.6) 0.0036 
*1 cycle-RDI (%) 51.7 (50–68.8) 75.0 (75.0–87.5) < 0.0001 
*2 cycle-RDI (%) 50.9 (37.5–59.0) 75.0 (75.0–84.4) < 0.0001 
DLTs With 26 (83.9%) 17 (39.5%) 
0.0001 
Without 5 (16.1%) 26 (60.5%) 
* Median (interquartile range) 
MSKCC, Memorial Sloan-Kettering Cancer Center; CRP, C-reactive protein; BMI, Body Mass Index; RDI, relative dose intensity; DLTs, dose limiting 
toxicities 
